PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
ALPCO

Press Release

Share      Blog

Receive press releases from ALPCO: By Email PDF Version RSS Feeds:

New Ultrasensitive Active GLP-1 ELISA to Confidently Measure Fasted Levels of Active GLP-1


ALPCO has released its new STELLUX® Chemiluminescent Ultrasensitive Active GLP-1 ELISA, the most sensitive active GLP-1 assay on the market.

New Ultrasensitive Active GLP-1 ELISA to Confidently Measure Fasted Levels of Active GLP-1
Salem, NH, November 09, 2016 --(PR.com)-- ALPCO has released its new STELLUX® Chemiluminescent Ultrasensitive Active GLP-1 ELISA (7-36) amide, the most sensitive active GLP-1 assay on the market. The new ELISA features a sensitivity of 0.06 pM, requires 25 µL of sample, and is specific to detect GLP-1 (7-36) amide which is the major biologically active form of GLP-1. As compared to other kits on the market, the STELLUX® Chemiluminescent Ultrasensitive Active GLP-1 ELISA (7-36) amide can be run in three hours or less due to fewer incubation steps and no extraction steps.

“Studying the role of GLP-1 has become crucial to understand more about insulin resistance,” explains ALPCO’s President, Sean Conley. “We developed the new STELLUX® Chemiluminescent Ultrasensitive Active GLP-1 ELISA to allow researchers to confidently study fasted levels of GLP-1, which has proven to be a challenge when using other assays available on the market.”

The STELLUX® Chemiluminescent Ultrasensitive Active GLP-1 ELISA (7-36) amide is For Research Use Only in the United States. It has also been demonstrated that the assay does not cross-react with any pro-glucagon derived fragments.

About ALPCO
American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since grown into a premier channel representing over 60 collaborating partners from around the globe. In 2008, ALPCO expanded its capabilities with the launch of an organically developed product line focused in the area of diabetes and obesity research while also remaining true to its roots by continuing to provide “Immunoassays Beyond the Ordinary.”
Contact Information
ALPCO
Nirja Patel
1-800-592-5726
Contact
www.alpco.com

Click here to view the list of recent Press Releases from ALPCO
Promote Your Business